d Our research strategy - RNID

Old name, new purpose: why we’ve gone back to RNID

Our research strategy

Our strategy outlines the approach we’re taking to speed up the discovery and development of treatments and cures for hearing loss and tinnitus. It highlights the areas of research we’ll fund and how we’ll support research in these areas.

We focus our research on:

Preventing hearing loss

We will fund research to:

    • better understand the cellular and molecular mechanisms that underlie hearing difficulties

    • advance the developments and testing of treatments to prevent any type of hearing disorder.

Restoring hearing

We will fund research that will:

    • lead to transformative improvements to the quality of hearing gained from medical devices

    • advance the discovery, developments and testing of drug, gene or cell-based therapies to repair damage to any part of the auditory system to improve hearing.

Silencing tinnitus

We will fund research that will:

    • improve our understanding of the biological mechanisms involved in tinnitus

    • develop and test new approaches to reduce the perception of tinnitus.

Developing the field

Through a range of funding schemes and the Hearing Therapeutics Initiative, we will:

  • accelerate the discovery and development of new treatments
  • develop future research leaders
  • be beneficiary-focused and inspire support.

Our position on the use of animals in research

We’re dedicated to supporting biomedical research into treatments and cures for hearing loss and tinnitus. Much of this research is carried out without using animals but, in certain areas, animal research remains essential if we are to understand hearing loss and tinnitus and develop new and effective treatments.

Research involving animals only takes place where there is no alternative available. We’re a member of the Association of Medical Research Charities (AMRC) and we support the AMRC principles of using animals in research.

Download our Biomedical Research Strategy 2020 (PDF, 278KB)

Page last updated: 18 October 2023

Back to top